Literature DB >> 30249611

GPs' experiences and perceptions of early detection of liver disease: a qualitative study in primary care.

Holly C Standing1, Helen Jarvis2, James Orr3, Catherine Exley1, Mark Hudson3, Eileen Kaner2, Barbara Hanratty2.   

Abstract

BACKGROUND: The incidence of liver disease is increasing in the UK and primary care is a key setting where improvement in the detection and management of liver disease is required. Little is known about GPs' understanding and confidence in detecting liver disease. AIM: To explore GPs' experiences of liver disease with a focus on early detection and interpretation of liver function tests (LFTs). DESIGN AND
SETTING: A qualitative study employing semi-structured interviews of a purposive sample of GPs from five UK primary care study sites.
METHOD: Telephone and face-to-face interviews of GPs were undertaken. Data were analysed thematically, using a constant comparative approach.
RESULTS: From a total of 25 GP interviews (N = 25), four themes were identified from the data: test-requesting behaviour, confidence and challenges in diagnosing disease, access to specialist tests, and guidance and education. Participants' descriptions of how they request and interpret LFTs varied widely. Concern over missing diagnoses was a common reason for requesting blood tests; patients with mildly abnormal LFTs and those at risk of non-alcoholic fatty liver disease (NAFLD) were a particular cause of concern. GPs saw themselves as generalists, with a reluctance to take on specialist investigations. Guidelines promoted confidence for some clinicians, but others felt that liver disease was too complex to be amenable to simple instructions. Most felt that they did not have access to relevant, focused education on liver disease.
CONCLUSION: Liver disease is not perceived as a priority in primary care. If GPs are to take on a greater role in identification and management of liver disease, support is needed to promote awareness, knowledge, and confidence. © British Journal of General Practice 2018.

Entities:  

Keywords:  United Kingdom; early diagnosis; general practice; liver diseases; liver function tests

Mesh:

Year:  2018        PMID: 30249611      PMCID: PMC6193778          DOI: 10.3399/bjgp18X699377

Source DB:  PubMed          Journal:  Br J Gen Pract        ISSN: 0960-1643            Impact factor:   5.386


  19 in total

Review 1.  Non-Alcoholic Fatty Liver Disease (NAFLD): new challenge for general practitioners and important burden for health authorities?

Authors:  Mohamed H Ahmed; Emmanuel O Abu; Christopher D Byrne
Journal:  Prim Care Diabetes       Date:  2010-03-17       Impact factor: 2.459

2.  Management of liver cirrhosis between primary care and specialists.

Authors:  Ignazio Grattagliano; Enzo Ubaldi; Leonilde Bonfrate; Piero Portincasa
Journal:  World J Gastroenterol       Date:  2011-05-14       Impact factor: 5.742

3.  Effect of body mass index and alcohol consumption on liver disease: analysis of data from two prospective cohort studies.

Authors:  Carole L Hart; David S Morrison; G David Batty; Richard J Mitchell; George Davey Smith
Journal:  BMJ       Date:  2010-03-11

4.  Body mass index and risk of liver cirrhosis in middle aged UK women: prospective study.

Authors:  Bette Liu; Angela Balkwill; Gillian Reeves; Valerie Beral
Journal:  BMJ       Date:  2010-03-11

5.  Acceptability of screening for early detection of liver disease in hazardous/harmful drinkers in primary care.

Authors:  Caroline Eyles; Michael Moore; Nicholas Sheron; Paul Roderick; Wendy O'Brien; Geraldine M Leydon
Journal:  Br J Gen Pract       Date:  2013-08       Impact factor: 5.386

6.  Are the opportunities to prevent alcohol related liver deaths in the UK in primary or secondary care? A retrospective clinical review and prospective interview study.

Authors:  Clare Verrill; Stewart Smith; Nick Sheron
Journal:  Subst Abuse Treat Prev Policy       Date:  2006-06-15

7.  Direct targeting of risk factors significantly increases the detection of liver cirrhosis in primary care: a cross-sectional diagnostic study utilising transient elastography.

Authors:  David J Harman; Stephen D Ryder; Martin W James; Matthew Jelpke; Dominic S Ottey; Emilie A Wilkes; Timothy R Card; Guruprasad P Aithal; Indra Neil Guha
Journal:  BMJ Open       Date:  2015-05-03       Impact factor: 2.692

8.  Awareness of nonalcoholic steatohepatitis and associated practice patterns of primary care physicians and specialists.

Authors:  Susan Polanco-Briceno; Daniel Glass; Mark Stuntz; Alexis Caze
Journal:  BMC Res Notes       Date:  2016-03-11

9.  Guidelines on the management of abnormal liver blood tests.

Authors:  Philip N Newsome; Rob Cramb; Suzanne M Davison; John F Dillon; Mark Foulerton; Edmund M Godfrey; Richard Hall; Ulrike Harrower; Mark Hudson; Andrew Langford; Anne Mackie; Robert Mitchell-Thain; Karen Sennett; Nicholas C Sheron; Julia Verne; Martine Walmsley; Andrew Yeoman
Journal:  Gut       Date:  2017-11-09       Impact factor: 23.059

Review 10.  Current and future pharmacological therapies for NAFLD/NASH.

Authors:  Yoshio Sumida; Masashi Yoneda
Journal:  J Gastroenterol       Date:  2017-12-16       Impact factor: 7.527

View more
  12 in total

Review 1.  Defining comprehensive models of care for NAFLD.

Authors:  Manuel Romero-Gómez; Jörn M Schattenberg; Jeffrey V Lazarus; Quentin M Anstee; Hannes Hagström; Kenneth Cusi; Helena Cortez-Pinto; Henry E Mark; Michael Roden; Emmanuel A Tsochatzis; Vincent Wai-Sun Wong; Zobair M Younossi; Shira Zelber-Sagi
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-06-25       Impact factor: 46.802

2.  The pathway to better primary care for chronic liver disease.

Authors:  Helen Jarvis; Stuart McPherson; Quentin M Anstee; Barbara Hanratty
Journal:  Br J Gen Pract       Date:  2021-03-26       Impact factor: 5.386

Review 3.  Redefinition of Fatty Liver Disease from NAFLD to MAFLD through the Lens of Drug Development and Regulatory Science.

Authors:  Yasser Fouad; Melissa Palmer; Minjun Chen; Arie Regev; Rajarshi Banerjee; Rob Myers; Robert Riccio; Richard Torstenson; Ramy Younes; Puneet S Arora; Henrik Landgren; Morten A Karsdal; Martin Blake; David A Shapiro; Hans-Juergen Gruss; Muhammad Y Sheikh; Dina Attia; Steven Bollipo; Alastair D Smith; Bradley Freilich; Robert G Gish; Detlef Schuppan
Journal:  J Clin Transl Hepatol       Date:  2021-10-22

4.  Development and validation of a prediction model to estimate the risk of liver cirrhosis in primary care patients with abnormal liver blood test results: protocol for an electronic health record study in Clinical Practice Research Datalink.

Authors:  Suvi Härmälä; Alastair O'Brien; Constantinos A Parisinos; Kenan Direk; Laura Shallcross; Andrew Hayward
Journal:  Diagn Progn Res       Date:  2019-05-23

5.  Healthcare practitioners' experiences of an intervention to detect and treat patients with liver disease (the LOCATE intervention): a qualitative process evaluation.

Authors:  Tina Reinson; Katherine Bradbury; Michael Moore; Nick Sheron
Journal:  BMJ Open       Date:  2019-05-22       Impact factor: 2.692

6.  Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD: real-world study of 18 million patients in four European cohorts.

Authors:  Myriam Alexander; A Katrina Loomis; Johan van der Lei; Talita Duarte-Salles; Daniel Prieto-Alhambra; David Ansell; Alessandro Pasqua; Francesco Lapi; Peter Rijnbeek; Mees Mosseveld; Dawn M Waterworth; Stuart Kendrick; Naveed Sattar; William Alazawi
Journal:  BMC Med       Date:  2019-05-20       Impact factor: 8.775

7.  Liver function tests and metabolic-associated fatty liver disease: Changes in upper normal limits, does it really matter?

Authors:  Roberta Forlano; Benjamin H Mullish; Ameet Dhar; Robert D Goldin; Mark Thursz; Pinelopi Manousou
Journal:  World J Hepatol       Date:  2021-12-27

8.  The egyptian clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease.

Authors:  Yasser Fouad; Gamal Esmat; Reda Elwakil; Serag Zakaria; Ayman Yosry; Imam Waked; Maissa El-Razky; Wahid Doss; Magdy El-Serafy; Ebraheem Mostafa; Mahmood Anees; Mohamed A Sakr; Nadia AbdelAty; Ashraf Omar; Samy Zaki; Amgad Al-Zahaby; Hamdy Mahfouz; Maysaa Abdalla; Mahmoud Albendary; Abdel-Khalek Hamed; Ahmed Gomaa; Adel Hasan; Sherif Abdel-Baky; Medhat El Sahhar; Gamal Shiha; Dina Attia; Ebada Saeed; Enas Kamal; Shamardan Bazeed; Mai Mehrez; Shereen Abdelaleem; Yasmine Gaber; Mohammed Abdallah; Asmaa Salama; Doaa A Tawab; Shaymaa Nafady
Journal:  Saudi J Gastroenterol       Date:  2022 Jan-Feb       Impact factor: 2.485

9.  Early prediction of incident liver disease using conventional risk factors and gut-microbiome-augmented gradient boosting.

Authors:  Yang Liu; Guillaume Méric; Aki S Havulinna; Shu Mei Teo; Fredrik Åberg; Matti Ruuskanen; Jon Sanders; Qiyun Zhu; Anupriya Tripathi; Karin Verspoor; Susan Cheng; Mohit Jain; Pekka Jousilahti; Yoshiki Vázquez-Baeza; Rohit Loomba; Leo Lahti; Teemu Niiranen; Veikko Salomaa; Rob Knight; Michael Inouye
Journal:  Cell Metab       Date:  2022-03-29       Impact factor: 31.373

10.  Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO).

Authors: 
Journal:  Eat Weight Disord       Date:  2021-12-16       Impact factor: 3.008

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.